News Highlights

May 6, 2013
Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds

February 26, 2013
Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate

February 19, 2013
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease

more...

Concert Cares

Concert walked in the NKF’s Boston Walk to help raise kidney disease awareness.

Welcome to Concert

Concert uses deuterium-based chemistry to create and develop highly differentiated new medicines by leveraging decades of pharmaceutical and clinical experience to reduce time, risk and expense.

Concert in the news... a selection of news stories featuring Concert.

Healthcare Global With the innovation of implementing deuterium, Concert Pharmaceuticals Inc. is demonstrating itself a pioneer in the world of science. Read more

Issued U.S. Patents

Concert is building a broad patent estate. View List

Upcoming Events

Concert will present at the Wells Fargo Healthcare Conference on June 18, 2013 in Boston.

Business Development/Strategic Partnering

Concert will present at the Translational CNS Summit taking place May 21-23, 2013 in Boston.